SILO Silo Pharma, Inc.
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.…
Industry Peers
BiotechnologyKey Statistics
About Silo Pharma (NASDAQ: SILO)
›
Silo Pharma (NASDAQ: SILO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 3 employees.
The shares were at 1.840 USD on 13 November 2026, down 72.8% over 52 weeks. Its 52-week range is 1.100 USD to 10.43 USD: the price is 82.4% below the high and 67.3% above the low.
Its market capitalisation is 4.30M USD.
Silo Pharma reports return on equity of -67.0%.
It holds more cash than debt, a net cash position of 5.23M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.